Want to see TSE:HBP full AI Analyst Report?
HBP Stock Chart & Stats
C$2.40
-C$0.03(-3.23%)
At close: 4:00 PM EST
C$2.40
-C$0.03(-3.23%)
Day’s Range― - ―
52-Week RangeC$0.95 - C$5.40
Previous CloseN/A
Volume518.00
Average Volume (3M)13.00K
Market Cap
C$106.93M
Enterprise ValueC$111.32M
Total Cash (Recent Filing)C$2.84M
Total Debt (Recent Filing)C$359.00K
Price to Earnings (P/E)―
Beta2.14
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding76,378,100
10 Day Avg. Volume29,165
30 Day Avg. Volume13,000
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.83
Price to Sales (P/S)0.00
P/FCF Ratio-15.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Solvency BufferVery low debt relative to equity materially reduces near-term solvency and interest burden risk, giving management flexibility to prioritize R&D and clinical progress. This balance-sheet strength supports funding runway and strategic options over the next several months without urgent refinancing.
Recapitalization: Turnaround To Positive EquityRestoring positive equity signals successful recapitalization and improved stakeholder confidence, which stabilizes capital structure and reduces existential solvency concerns. That structural improvement creates a firmer platform to advance clinical programs and attract partner or investor support.
Focused R&D Asset-light Business ModelA tight, R&D-centric operating model with a very small headcount reduces fixed-cost burden and enables capital to be concentrated on advancing drug candidates. This asset-light structure improves the efficiency of each funding dollar and preserves runway while programs progress through development stages.
Bears Say
Pre-revenue With Persistent Operating LossesAbsence of product revenue and recurring operating losses mean the company depends on external financing to sustain operations. Over 2–6 months this structural gap constrains strategic flexibility, limits self-funding of trials, and makes progress contingent on capital availability rather than operating cash generation.
Negative Operating And Free Cash FlowSustained negative operating/free cash flow indicates ongoing cash burn that will necessitate financing actions or cost containment. This pressure can delay programs, force dilutive equity raises, or bargain partnership terms; cash-flow weakness is a durable constraint on executing clinical milestones.
No Revenue Base Undermines Earnings QualityWithout a top-line foundation, fixed and development costs remain unabsorbed, keeping margins structurally negative. This limits ability to demonstrate sustainable profitability or internal funding, leaving R&D progress and corporate viability dependent on external capital and partnership execution.
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.95 and its highest was C$5.40 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$106.93M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Nov 04, 2026 which is in 122 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Jun 10, 2026. The company reported -C$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.009.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 76,378,100 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.947%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Helix BioPharma
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
Technical Analysis
Satellos Bioscience
―
Arch Biopartners
―
Medicenna Therapeutics Corp
―
ME Therapeutics Holdings, Inc.
―
Onco-Innovations Ltd.
―
Options Prices
Currently, No data available
---